DPP4 inhibitor requiring dose reduction in both liver and kidney failure
**Core Concept**
The question tests the understanding of **Dipeptidyl Peptidase-4 (DPP4) inhibitors**, a class of oral hypoglycemic agents used in the treatment of type 2 diabetes mellitus. DPP4 inhibitors work by inhibiting the enzyme **DPP4**, which is responsible for the inactivation of **incretin hormones**.
**Why the Correct Answer is Right**
The correct answer is a DPP4 inhibitor that requires dose adjustment in both hepatic and renal impairment, reflecting its pharmacokinetic profile. This is crucial because both liver and kidney play significant roles in the metabolism and excretion of drugs. A drug requiring dose reduction in both liver and kidney failure indicates its dependence on these organs for its elimination.
**Why Each Wrong Option is Incorrect**
**Option A:** Incorrect because it does not require dose reduction in both liver and kidney failure.
**Option B:** Incorrect as its dosing is not significantly affected by both hepatic and renal function.
**Option C:** Incorrect due to its pharmacokinetic profile not necessitating dose adjustments in both liver and kidney impairment.
**Option D:** This is the correct choice, as **Linagliptin** is known for requiring dose adjustments in patients with both hepatic and renal impairments, although it's primarily renally excreted, its hepatic metabolism also plays a role.
**Clinical Pearl / High-Yield Fact**
It's crucial to remember that **Linagliptin** has a unique pharmacokinetic profile compared to other DPP4 inhibitors, with a primary route of excretion being the bile and gut, but its dose still needs to be adjusted in renal impairment, and careful consideration in hepatic impairment.
**Correct Answer:** D. Linagliptin